- This is a T-cell vaccine given via subcutaneous injection every four weeks. In this process, myelin-reactive T cells are removed from a small amount of the patient's blood, inactivated, and then injected back into the patient. The body's immune system then protects the myelin from these cells.
- A Phase II study showed significant improvements in the annualized relapse rate of patients with RRMS or SPMS. A decrease in myelin-reactive T cells in the blood was also found.
- TERMS is an ongoing placebo-controlled one-year study in patients with CIS and RRMS to evaluate Tovaxin's efficacy, safety and tolerability. Patients in the trial also participated in an open-label, one-year extension study. The treatment was found to be safe, but did not achieve statistical significance in the primary endpoint, which was a reduction in the cumulative number of gadolinium-enhancing lesions as compared to placebo. Therefore, a larger study in RRMS patients is planned.